Lobbying disclosures · Lobbying report
MRK: second_quarter 2026 lobbying report
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pr
Follow MRK- Became public
- Jul 20, 2026, 11:40 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 8:11 AM EST
Why this is connected
Exact legal-name match: Merck & Co., Inc. (https://www.sec.gov/Archives/edgar/data/310158/).
Reported lobbying amounts
Expenses: $2,270,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/abdf6f60-b8ba-4e2c-88ca-fc52436b6865/","filing_uuid":"abdf6f60-b8ba-4e2c-88ca-fc52436b6865","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/abdf6f60-b8ba-4e2c-88ca-fc52436b6865/print/","filing_document_content_type":"text/html","income":null,"expenses":"2270000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brad Tallamy","dt_posted":"2026-07-20T11:40:59-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"126 E Lincoln Avenue","registrant_address_2":"P.O. Box 2000","registrant_different_address":false,"registrant_city":"Rahway","registrant_state":"NJ","registrant_zip":"07065","registrant":{"id":24908,"url":"https://lda.gov/api/v1/registrants/24908/","house_registrant_id":31304,"name":"MERCK & CO, INC.","description":null,"address_1":"126 E Lincoln Avenue","address_2":"P.O. Box 2000","address_3":null,"address_4":null,"city":"Rahway","state":"NJ","state_display":"New Jersey","zip":"07065","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRAD TALLAMY","contact_telephone":"+1 202-508-4545","dt_updated":"2026-07-30T11:53:36.976270-04:00"},"client":{"id":132602,"url":"https://lda.gov/api/v1/clients/132602/","client_id":12,"name":"MERCK & CO INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-13"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67281,"prefix":null,"prefix_display":null,"first_name":"BRADLEY","nickname":null,"middle_name":"ALLEN","last_name":"ROSSIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69077,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"SCHWARTZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":119825,"prefix":null,"prefix_display":null,"first_name":"BRADFORD","nickname":null,"middle_name":null,"last_name":"TALLAMY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149596,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MCBATH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153657,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"RADDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154457,"prefix":null,"prefix_display":null,"first_name":"CHARLES","nickname":null,"middle_name":null,"last_name":"CLAPTON","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Cmte; Chief Health Counsel, House Ways & Means Cmte; Policy Advisor, Rep. Hastert; Health Policy Dir., Senate Health, Education, Labor, and Pensions Cmte.","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues relating to, One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Cost and value of medicines: Drug pricing and reimbursement issues; FY-2027 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67281,"prefix":null,"prefix_display":null,"first_name":"BRADLEY","nickname":null,"middle_name":"ALLEN","last_name":"ROSSIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69077,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"SCHWARTZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":119825,"prefix":null,"prefix_display":null,"first_name":"BRADFORD","nickname":null,"middle_name":null,"last_name":"TALLAMY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153657,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"RADDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154457,"prefix":null,"prefix_display":null,"first_name":"CHARLES","nickname":null,"middle_name":null,"last_name":"CLAPTON","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Cmte; Chief Health Counsel, House Ways & Means Cmte; Policy Advisor, Rep. Hastert; Health Policy Dir., Senate Health, Education, Labor, and Pensions Cmte.","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues relating to, Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes; Tax Cuts and Jobs Act (P.L. 115-97), provisions relating to tax reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67281,"prefix":null,"prefix_display":null,"first_name":"BRADLEY","nickname":null,"middle_name":"ALLEN","last_name":"ROSSIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69077,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"SCHWARTZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154457,"prefix":null,"prefix_display":null,"first_name":"CHARLES","nickname":null,"middle_name":null,"last_name":"CLAPTON","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Cmte; Chief Health Counsel, House Ways & Means Cmte; Policy Advisor, Rep. Hastert; Health Policy Dir., Senate Health, Education, Labor, and Pensions Cmte.","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ANI","general_issue_code_display":"Animals","description":"Issues relating to, Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill, 2026; Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026; Interior, Environment, and Related Agencies Appropriations Bill 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149596,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MCBATH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67281,"prefix":null,"prefix_display":null,"first_name":"BRADLEY","nickname":null,"middle_name":"ALLEN","last_name":"ROSSIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154457,"prefix":null,"prefix_display":null,"first_name":"CHARLES","nickname":null,"middle_name":null,"last_name":"CLAPTON","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Cmte; Chief Health Counsel, House Ways & Means Cmte; Policy Advisor, Rep. Hastert; Health Policy Dir., Senate Health, Education, Labor, and Pensions Cmte.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in MRK
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 2, 2026 · disclosed Nov 5, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
Sold (partial) Merck & Co. MRK
$1K–$15K · Traded Sep 24, 2026 · disclosed Oct 7, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Sep 9, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Aug 19, 2026 · disclosed Sep 9, 2026
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 30, 2026$1K–$15K
Rep. Keith Self (R-TX-3)
$1K–$15K · Traded Jan 10, 2025 · disclosed Jun 30, 2026 · filed 536 days later
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.